급성 관상동맥 증후군 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global acute coronary syndrome market size is expected to reach USD 18.13 Billion in 2034 from USD 10.47 Billion in 2025, growing at a CAGR of 6.29 during 2026-2034.This market is witnessing steady expansion as cardiovascular diseases remain one of the leading causes of mortality worldwide. Acute coronary syndrome includes life-threatening conditions such as unstable angina and myocardial infarction that require immediate diagnosis and treatment. Growing awareness regarding early cardiac intervention, expanding healthcare infrastructure, and continuous advancements in therapeutic options are contributing to increased market demand. Rising investments in cardiovascular care are further supporting industry development.

Increasing prevalence of lifestyle-related risk factors including obesity, diabetes, hypertension, and smoking is a major driver of market growth. Healthcare providers are adopting advanced diagnostic technologies, minimally invasive procedures, and innovative pharmaceutical therapies to improve patient outcomes. Ongoing research in antiplatelet drugs, anticoagulants, and interventional cardiology devices continues expanding treatment options. Government initiatives promoting cardiovascular disease prevention and early diagnosis are also strengthening market expansion globally.

Future prospects remain highly positive as healthcare systems continue emphasizing preventive cardiology and personalized treatment strategies. Artificial intelligence-assisted diagnostics, wearable cardiac monitoring devices, and precision medicine approaches are expected to improve early detection and clinical management. Increasing investments in cardiovascular research and healthcare accessibility will generate significant opportunities for pharmaceutical and medical device manufacturers. Continued innovation will sustain long-term market growth worldwide.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• Non-ST-elevation Myocardial Infarction (NSTEMI)
• ST-elevation Myocardial Infarction (STEMI)
• Unstable Angina

By Drug Class

• Antiplatelet Therapy
• Anticoagulants
• Beta Blockers
• Nitrates
• Thrombolytics
• Other Medications

By Route of Administration

• Oral
• Injectables

By Age Group

• Adult
• Geriatric

By End Use

• Hospitals
• Cardiology Clinics
• Ambulatory Surgical Centers
• Other End Use

COMPANIES PROFILED

• AstraZeneca, Azurity Pharmaceuticals, Baxter Healthcare, Boehringer Ingelheim, Bristol Myers Squibb, Cipla, Eli Lilly, Genentech, Intas Pharmaceuticals, Janssen Pharmaceuticals, Merck, Novartis, Pfizer, Sanofi

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ACUTE CORONARY SYNDROME MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Non-ST-elevation Myocardial Infarction (NSTEMI) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. ST-elevation Myocardial Infarction (STEMI) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Unstable Angina Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ACUTE CORONARY SYNDROME MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. Antiplatelet Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Anticoagulants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Beta Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Nitrates Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Thrombolytics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Other Medications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ACUTE CORONARY SYNDROME MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injectables Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ACUTE CORONARY SYNDROME MARKET: BY AGE GROUP 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Age Group
• 7.2. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Geriatric Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ACUTE CORONARY SYNDROME MARKET: BY END USE 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast End Use
• 8.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Cardiology Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Ambulatory Surgical Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Other End Use Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ACUTE CORONARY SYNDROME MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Type
  • 9.2.2 By Drug Class
  • 9.2.3 By Route Of Administration
  • 9.2.4 By Age Group
  • 9.2.5 By End Use
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Type
  • 9.3.2 By Drug Class
  • 9.3.3 By Route Of Administration
  • 9.3.4 By Age Group
  • 9.3.5 By End Use
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Type
  • 9.4.2 By Drug Class
  • 9.4.3 By Route Of Administration
  • 9.4.4 By Age Group
  • 9.4.5 By End Use
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Type
  • 9.5.2 By Drug Class
  • 9.5.3 By Route Of Administration
  • 9.5.4 By Age Group
  • 9.5.5 By End Use
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Type
  • 9.6.2 By Drug Class
  • 9.6.3 By Route Of Administration
  • 9.6.4 By Age Group
  • 9.6.5 By End Use
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL ACUTE CORONARY SYNDROME INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 AstraZeneca
  • 11.2.2 Azurity Pharmaceuticals
  • 11.2.3 Baxter Healthcare
  • 11.2.4 Boehringer Ingelheim
  • 11.2.5 Bristol Myers Squibb
  • 11.2.6 Cipla
  • 11.2.7 Eli Lilly
  • 11.2.8 Genentech
  • 11.2.9 Intas Pharmaceuticals
  • 11.2.10 Janssen Pharmaceuticals
  • 11.2.11 Merck
  • 11.2.12 Novartis
  • 11.2.13 Pfizer
  • 11.2.14 Sanofi